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Epinephrine promotes resuscitation from ventricular fiheil-
l∎tfon because of Its
peripheral vasocomarlctlve effects.
However, the (seta-ulveaergk efeots ofepinephrine may he
detrimental because of the stimulation of myocardial oxy .
gen demand. To test whether functional recovery from
fibrillation in hearts treated with a selective alpha.
adrenergic agent Is greater than in hearts treated with
epinephrine, ventricular fibrillation was induced in eight
isolated dog hearts while coronary perfusion pressure was
maintained at 30 mm Hg. In random order, epinephrine
(5 pg/min), phenyiephrine (50
pig/min)
or no drug was
infused for S min. The heart was then defibrillated, the
drug Infusion stopped and coronary perfusion pressure
increased to 100 mm Hg.
Coronary blood flow (mVmin per 100 g), arteriovenoos
oxygen difference (ml 0,/dl) and myocardial oxygen con-
sumption (ml O,lmia per 100 g) measured after 4 min of
ventricular fibrillation were greater with epinephrine
(mean ± SD 30 .9 ± 11 .7, 17.5 t 1.6 and 5 .4 2 1.9,
respectively) than with phenylephrine (24.4 ± 6.0, 15.7 se
Epinephrine, a mixed alpha- and beta-adrenergic agonist, is
of proven value in experimental models of resuscitation from
ventricular fibrillation (1,2). In the clinical setting, it has
been a drug of choice for more than a decade (3,4)
.
Available
evidence shows that the peripheral vasoconstrictive (that is,
alpha-adrettergic) effects of high dose epinephrine account
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p c 0.05, respecNrdy)
. The stop, at the end-systagc
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restoration of normal coronary perfusion pinion was
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.
Volume axis intercepts (Vs) were s o different (p = NS) .
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perfusion
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increased oxygen denwd and iekuYrwdon of kchemla,
whereas the benefit of pheegkpbrine seems to be the result
of a weak and
pule"
positive lnotrr,ptc effect .
(J
Am Cull Car" 1990;16.'089-94)
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for its benefit during resuscitation by increasing coronary
perfusion pressure (5) and thus improving coronary flow (6) .
At the same time, the beta-adrenergic effects of epinephrine
may be deleterious during resuscitation . A fibrillatiog heart
consumes oxygen at a high rate (7,8) and inotropic stimula-
tion may further increase oxygen aemand
(9),
resulting in
exacerbation of myocardial ischemia
(l0). In addition to
arterial perfusion pressure, myocardial wall tension is an
important determinant of myocardial blood flow
. By increas-
ing the mechanical vigor of fibrillation . positive inotropic
agents such as epinephrine may reduce myocardial perfusion
(11 .12) . As judged by the frequency with which defibrillation
is followed by electromechanical dissociation and death,
these processes may be
particularly important at the low
perfusion pressures characteristic of cardiopulmonary resus-
citation .
Relative to epinephrine, an alpha-adrenergic agonist
would appear to offer the advantages of peripheral vasocon-
0735-1097/9wr3.50
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striction and maximization of coronary perfusion pressure
without the disadvantages of increased myocardial oxygen
demand or increased wall tension . This might lcid to better
ventricular function immediately after defibrillation and,
possibly, improved survival .
In this study, we measured ventricular function in the dog
heart after a 5 min period of ventricular
fibrillation at
constant low coronary perfusion pressure. In this way,
experimental conditions were analogous to those of cardiac
arrest and external chest compression
. The heart was treated
with epinephrine, phenylephrine
or no drug during the
period of fibrillation, and ventricular function was measured
after a 10 min recovery period .
Methods
Surgical preparation
. This study conformed to the prin-
ciples outlined in the Position of the American Heart Asso-
ciation on Research Animal Use . Eight canine left ventricles
were studied in
an isolated perfused heart preparation,
which has been described previously (13,14) . In each exper-
iment, a pa:: of mongrel dogs was anesthetized with sodium
pentobarbital (30 mg/kg body weight
intravenously). The
femoral arteries and veins of one dog (support
dog) were
cannulated and connected to a constant
flow shunt, This
consisted of a heat exchanger and a fixed rate peristaltic
pump that was preset at the beginning of the experiment to
supply at least 250 ml/min of flow . Blood from the
shunt was
returned to the support dog after passing through
an air trap .
A perfusion system was connected to the shunt distal to the
fixed rate peristaltic pump. The perfusion
system consisted
of a servo-controlled peristaltic pump and a blood filter
.
Coronary venous drainage was returned to the support dog
IACC Vol . 16, No . 2
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Figure 1 . The isolated heart preparation . The donor
bean is perfused with arterial blood from a support
dog
. Coronary perfusion pressure was set at either 30
mm Hg for ischemic conditions or 100 mm Hg for
working conditions . A flood shunt of arterial blood was
created in the support animal to ensure that the
large
experimental fluctuations in coronary flow present in
the donor heap did not result in any change in demand
for blood flow from the support animal. A thin latex
balloon was placed in the left ventricle and mounted
in
the mitral anulus
. Volume was measured using a linear
displacement transducer. Pressure was measured us-
ing a micromanometer-tipped catheter within the left
ventricular (LV) cavity . The corollary sinus was can-
nututed and all Row from the sinus was measured with
an electromagnetic flow meter . Differences in arterial
and venous oxygen content were determined continu-
ously while an oximeter compared coronary sinus
blood with arterial blood
.
AVID., =
arteriovenous
oxygen difference .
through the same air trap used for constant flow shunt. In
this way, alterations in coronary perfusion pressure could be
made without affecting the amount of blood leaving or
returning to the circulation of the support animal . The details
of this system can be seen in Figure L
A vent was placed in the left ventricular cavity to allow
for drainage of thebesian flow. A water-filled balloon was
positioned inside the left ventricular cavity . The balloon was
connected to a piston pump capable of precisely measuring
and controlling ventricular volume . Coronary sinus flow was
diverted through a catheter to a magnetic flow meter (RT
400, Narco Bio-Systems) and then to an oximeter
(A-VOX
System) that compared its oxygen content with that of a
constant sampling of arterial blood . Thus, coronary sinus
flow, arteriovenous oxygen difference and oxygen consump-
tion could be measured continuously .
Protocol. The volume of the isolated heart was set at a
level that produced an initial end-diastolic pressure of 15 to
20 mm Hg. With coronary perfusion pressure maintained
at
100 mm Hg, instantaneous left ventricular pressure and
volume were recorded during isovolumetric contraction and
as end-diastolic volume was gradually reduced to a minimal
level . Next, coronary perfusion pressure was reduced to 30
mm Hg, left ventricular volume was set at 25 ml and
ventricular fibrillation was induced with rapid ventricular
pacing. In random order, infusion of either epinephrine
(5 (ag/min) or phenylephrine (50 pg/min) was added to the
coronary perfusion circuit . These doses were chosen to
simulate the high doses used clinically . Specifically, in pilot
studies, 5 µg/min of epinephrine reproducibly increased
peak developed pressure in isovolumetrically contracting
hearts by a factor of two to three. suggesting maximal or
near maximal cardiac beta-receptor saturation . The dose of
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phenylephrine was selected on the basis of peripheral vaso-
constrictive equivalence, as judged by the increase in aortic
diastolic pressure during cardiac arrest and external chest
compression in dogs
. In >10 such whole animal prepara-
tions, a bolus injection of epinephrine (0
.64 mgrkg) into the
left ventricle was always sufficient to elicit a full vasocon-
strictive response (2) . Phenylephrine (0 .2 mglkg) elicited a
full vasoconstrictive response in five other dogs, but a sixth
dog required a higher dose (0
.4 mg/kg), Consequently, the
10-fold higher dose of phenylephrine was chosen for this
study. This dose is consistent with the work of other
investigators (1,15,16) . Thus, the pharmacologic milieu re-
sembled that of cardiopulmonary resuscitation, with maxi-
mal or near maximal stimulation of inotropic slate and
vascular tone .
At the end of 5 min of fibrillation, the infusion was
discontinued, coronary perfusion pressure was returned to
100 mm Hg and the heart was defibrillated using a 10 J
countershock applied with epicardial defibrillator paddles .
A
10 min period of stabilization followed before measurements
of ventricular pressure-volume relations were repeated .
Ischemic fibrillation was then repeated with the alternative
agent
. In this way, separate data for infusion of epinephrine
or phenylephrine were obtained for each heart . Control
observations were made in five of the eight hearts after the
infusion of no drug, also in random sequence .
Data analysis . Data were collected digitally at a fre-
quency of 200 Hz and stored on a DEC model PDP-11
computer
. End-systolic pressure-volume relations were de-
termined using the maximal pressureivolume ratio for a
minimum of 30 isovolumetric beats . Comparisons of mean
data were made using analysis of variance and are described
throughout the manuscript as the mean value t SD .
Res - Its
Baseline ventricular function . The slope and volume axis
intercept for the initial end-systolic pressure-volume relation
averaged 3.9 ± 1 .2 mm Hg/ml and 4.9 ± 2 .2 ml, respectively,
for the eight hearts
. The end-systolic pressure-volume rela-
tion was determined over a range of volumes that began at a
highest volume of 39 ± 3 ml and ended at a lowest volume of
II ± 3 ml . These volumes corresponded to a highest
end-diastolic pressure of 13 .5 ± 3 .0 mm Hg a :nd a lowest
pressure of 2.6 ± 1 .7 mm I(g . Mean coronary flow for the
working ventricle at highest end-diastolic volume and a
coronary perfusion pressure of 101 mm Hg was 79
.2 ± 14.0
ml/min per 100 g and arteriovenous oxygen difference aver-
aged 7,6
t
1,2 ml/10O ml, yielding a mean oxygen consump-
tion value of 6 .0 a 1 .6 mi/min per 100 g .
Ventricular
fibrillation . Figure 2 shows an example of the
strip chart recordings obtained from one experiment before,
during and after an epinephrine-treated fibrillation period .
lntraventricular pressure was recorded during isovolumetric
MIDE1 Er AL
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contraction
. Ventricular volume was reduced slowly so that
a minimum of 30 ventricular beats were recorded over a wide
volume range . Measurements of coronary sinus flow and
arteriovenous oxygen difference were made 4 min after the
fibrillation period began while coronary perfusion pressure
was maintained at 30 mm Hg
.
Coronary flow, arteriovenous oxygen difference
and oxy-
gen consumption were highest during epinephrine
infusion,
intermediate for phenytepbnne infusion and lowest for no
drug infusion, and each was significantly different for the
three conditions (Fig. 3). For the respective conditions,
coronary flow averaged 33 .7 ± .9,278t6.2 and 22.8 ±:5 .6
ml/min
per 100 g (p < 0.05)
. The corresponding arteriove-
nous oxygen differences were 18 ± 2, 16
.5 ± 2 .5 and 14.4 ±
2.3 ml/100 ml (p < 0.05)
. These values yielded oxygen
consumption values of 6.1 ± 1
.3, 4 .6 ± 1 .2 and 3 .2 *_ 0.8
ml/min per 100 g (p < 0.05) .
Left venkknpw fmclktr after
deitagWon
.
Relative to
prefibrillation values, the slope of the end-systolic pressure-
volume relation (E0s
) remained depressed 10 min after
termination of the epinephrine infusion and restoration of
100 mm Hg coronary perfusion pressure
. It was not signifi-
cantly changed 10 min after infusion of no drug and was
increased after infusion of phenylephrine (Fig
. 4) . The slope
of the end-systolic pressure-volume relation was only 72 ±
17% of control 10 min after epinephrine, increased to 143 ±
17% of control after phenylephrine and was 82 t
12% of
control after no drug infusion (Fig . 5)
. These differences are
highly significant (p < 0
.01). Changes in volume axis inter.
cept (V0
) before and after the fibrillation period averaged 0 .1
± 2 ml for the no drug period and were not significantly
different for epinephrine or phenylephrine .
End-diastolic pressure averaged 9 .5 t 2.5 mm Hg at high
end-diastolic volume before any given fibrillation period .
End-diastolic pressure at the mid-range volume was riot
changed significantly 10 min after defibrillation by epineph-
rine (10 ± 5 mm Hg) . phenylephrine (7 .1 ± 3
.4 mm Hg) orby
no drug (9.1 ± 5.4 mm Hg)
. End-diastolic pressure was also
measured at the low end of the range of volumes tested and
was found to be similar after all three interventions .
Discussion
Effect of epinepbrie on myoardld Iwetion . In this
study, we compared myocardial function as measured by the
end-systolic pressure-volume relation before and after a
5 min period of ischemic ventricular fibrillation, during
which time the heart was treated with either no drug,
epinephrine or phenylephrine. Drug doses were similar to
those used in cardiopulmonary resuscitation . Epinephrine
markedly increased oxygen consumption and, relative to
prefibrillation control values, caused a 28% decline in the
slope of the end-systolic pressure-volume relation (p <
0.05), whereas treatment with no drug was associated with a
492
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decrease of only 1g% (p = NS). This result is consistent with
the previous observation (10) that epinephrine aggravates
the ischemia of ventricular fibrillation at a low perfusion
pressure . Although phenylephrine also caused an increase in
myocardial oxygen consumption, phenylephrine infusion
during ischemic fibrillation was associated with an increase
in the slope of the end-systolic pressure-volume relation .
Measurements of left ventricular function were made rou-
tinely 10 min after defibrillation, but changes after drug
treatment were consistently present up to 30 min after
defibrillation in the three animals in which extended obser-
vations were made.
Survival from ventricular fibrillation depends on mainte-
nance of vital organ blood flow until spontaneous and
effective circulation can be restored . In animal studies
(1,2,6), high dose epinephrine increased myocardial and
cerebral blood flow during chest compression and promoted
resuscitation from ventricular fibrillation . The primary
mechanism for these effects is the alpha-adrenergically me-
diated vasoconstriction in tissues other than the heart and
tpF1rIW.1TuAWN
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Figure 2. An example of the strip
chart recording obtained before, dur-
ing and after a 5 min period of fibril-
lation, At point 1, the end-systolic
pressure-volume relation was deter-
mined under isovolumetric condi-
tions. For the purpose of illustration,
only a limited volume range is shown .
At point 2, coronary perfiusion pres-
sure was reduced to 30 non Hg, ven-
tricular fibrillation was induced and
intmarterial drug infusion begun . Bo-
tween points 2 and 4, the strip chart
speed was increased during computer
data sampling, which accounts for
some of the variation from curvilin-
eerily of the data. Point 3 was located
4 min into the fibrillation period, at
which time steady state arteriove
nous oxygen difference (AVOr) and
coronary flow are apparent . A mea-
surement of these variables was
made at point 3 . The 5 min fibrillation
period was over at point 4 . At this
stage, coronary perfusion pressure
was restored to 100 mm Hg, the heart
was defibrillated and the drug infu-
sion discontinued. A 10 min period of
equilibration followed. At point 5, the
end-systolic pressure-volume rela-
tion was measured again . In this ex-
ample, epinephrine was the drug ad-
ministered during the fibrillation
period . For a given volume, pressure
generated after the fibrillation period
is significantly lower than pressure
generated during the prefibrillation
control period . L V
= left ventricular
.
brain . Because epinephrine is also a strong beta-adrenergic
agonist, it is possible that epinephrine actually worsens
myocardial oxygen supply/demand balance in some cases .
The clinical consequence of this untoward effect would be
defibrillation followed by mechanical dysfunction so ex-
treme that the ventricle fails to generate adequate blood
pressure for its own survival. This is precisely the clinical
problem encountered most often in fatal ventricular fibrilla-
tion . Defibrillation is almost always possible, but patients
commonly remain pulseless or severely hypotensive after
defibrillation. A recent report (10) of decreased adenosine
triphosphate (ATP) in fibrillating hearts treated with epi-
nephrine suggests that epinephrine may exert a deleterious
effect in selected cases .
Epinephrine versus phenylephrlne effect on myocardial
function. In our studies, epinephrine increased oxygen con-
sumption in fibrillating hearts with reduced coronary perfu-
sion pressure, Myocardial contractility was reduced after
defibrillation, probably as a consequence of this intensifica-
tion of ischemia. Epinephrine had no measurable effect on
IACC Vol. 16, No. 2
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Figure 3. Data from the measurements made 4 min into the fibril .
lotion
period
for the three conditions. Epinephrine infusion during
ischemic fibrillation resulted in the highest measurements for corn
nary sinus flow (A), arteriovenous oxygen (O=) differences (B) and
myocardial oxygen consumption (C) . Measurements made during
phenylephrine infusion were intermediate and the lowest recordings
were made when neither drug was infused . Differences between
conditions were significant for all three variables .
diastolic function . When these same hearts were treated with
phenylephnne, an intermediate metabolic effect was ob-
served-oxygen consumption was higher than during no
drug, but significantly less than with epinephrine . This is
consistent with the previously observed (17,18) weak inotro-
pie effect of alpha,-aganists . However, after phenylephrine
treatment, a persistent increase in the end-systolic pressure-
volume relation slope (contractility) was observed . As in the
case of epinephrine, phenylephrine had no measurable effect
on diastolic function. It is possible that persistent alpha,-
adrenergic activity accounts for the improvement in ventric-
ular function that was present up to 30 min after defibrillation
in the hearts treated with phenylephrine (that is, phenyleph-
rine worsened the ischemia of ventricular fibrillation, but not
NIDEI ET AL .
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Figure 4. The slope of the end-systolic pressure-volume relation
(E-l (ordinate), determined before and after the fibrillation period
for the three conditions
. This slope declined significantly after
(POST) epinephrine infusion, increased after phenylephrine infusion
and was not changed significantly when no drug was infused . PRE _
before
.
by enough to negate a persistent positive inotropic effect 10
to 30 min later). Alternatively, an alpha,-mediated increase
in glycolysis could have improved the metabolic status of
these hearts relative to no drug or epinephrine (19)
.
Under
these conditions, increased oxygen consumption might
reflect increased pyruvate availability and increased tricar .
boxylic acid cycle activity rather than worsened ischemia .
This hypothesis is a better explanation for the persistence
of the improved contractile function after phenylephrine
and could also account for the patterns of oxygen consump-
tion and contractility that we observed . In either case, in
terms of preservation of myocardial function, phenyleph-
rine-associated alpha-adrenergic stimulation was, on bal-
ance, beneficial .
This study therefore confirms suspicions that under cer-
tain circumstances epinephrine has deleterious effects on
myocardial oxygen supply and demand during ischemia and
Figure 5
. Comparison of the percent change in the slope of the
end-systolic pressure-volume relation (E n,) after defibrillation
among groups . The slope declined to 72% of the control value after
the epinephrine-treated fibrillation period, but increased to 143% of
the control value after phcnylephrine infusion . The change when no
drug was infused was to an intermediate 82% of the control value .
The differences among groups were highly significant .
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ventricular fibrillation . In addition, our work shows that the
increased oxygen demand that accompanies epinephrine
infusion may have detrimental effects on ventricular function
after defibrillation. A recent comparative study (20) of phe-
nylephrine and epinephrine, which found no difference in
coronary perfusion or resuscitation, does not negate the
potential importance of these effects. In that study, coronary
perfusion pressures among surviving animals (26 ± 3 mm Hg
in the phenylephrine group) were substantially higher than
among nonsurvivors (15 ± 3
mm Hg)
. This may be too great
a difference in pressures to detect a relatively subtle meta-
bolic effect.
Limitations. We chose to study the effect of catechol-
amine infusion during fibrillation using the isolated dog heart
preparation because of the unique and accurate measure-
ment of left ventricular function it makes possible. Precise
control of load and the independent control of coronary
perfusion would not have been possible in a whole animal
preparation . At the same time, the use of this preparation
places some limitations on the interpretation of the results .
This study focuses on the effect of two drugs at the specific
loading and perfusion conditions that might be expected
during vigorous cardiopulmonary resuscitation . In intact
subjects undergoing resuscitation, these drugs could have
deleterious effects on organs other than the heart, and it is
possible that coronary perfusion pressure could be substan-
tially different from the level used in these studies .
Conclusions. Despite these limitations, it is apparent that
epinephrine administered during ventricular fibrillation
causes an increase in myocardial oxygen demand that is
associated with myocardial dysfunction in the early postde-
fibrillation period . This association is likely the result
of
intensification of myocardial ischemia caused by epineph-
rine. In equipotent vasoconstrictive doses, phenylephrine
induced only a small increase in oxygen consumption during
fibrillation and improved myocardial function in the postde-
fibrillation period
. Renewed investigation of this agent in
intact animal models of cardiac arrest seems appropriate .
We thank Linda Reed for assistance in the preparation of the manuscript .
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